Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2016 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of repeatable business escalating. We need to find if management conveys that deals, orders, contracts, projects, customers, sites, or programs are individually bigger, broader, or longer than before. Scanning the transcript: Management discusses various brands, growth, POS, etc. They talk about Barbie, Fisher-Price, Hot Wheels, Thomas, American Girl, MEGA, etc. They mention expansion of distribution, new partnerships, etc. But do they specifically say that the size of individual deals or contracts is escalating? For example, they mention "expanded distribution strategy" for American Girl, "new exclusive store within the store partnership with Toy [ph]" (likely Toys R Us), "new franchise licensing agreement to expand the brand into the Middle East." But that's about new partnerships, not necessarily larger size of same kind. They also mention "increased retailer confidence in the brand as they restock and expand our recent shelf space" for Barbie. That could be about more shelf space, but that's about volume, not necessarily larger individual deals. They talk about "continued international expansion" for MEGA, but again that's about more markets, not larger deals. They mention "new retail execution" and "new franchise licensing agreement" but not that these are larger than previous ones. They also mention "we continue to see real strength in our core brands" and "positive consumer takeaways aligning nicely with shipping." But no explicit statement about the size of individual engagements escalating. The question asks: "On this call, does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE?" We need to find if they say something like "our average order size is increasing" or "our new customers are starting at a larger scale than before" or "we are now landing larger contracts than we used to." I don't see any such statement. They talk about growth, but that could be from more units, more customers, more volume. They don't specifically say that each new deal is bigger than the last.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.